RET and neoplasm: In this phase 1/2 study of pralsetinib in patients with advanced or metastatic RET fusion–positive solid tumors, almost all of whom were previously treated with systemic therapy, pralsetinib showed robust and durable anti-tumor activity regardless of tumor type or RET fusion partner.